Περίληψη:
Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in choosing the right treatment, the best timing of administration, consequently trying to maximize drug efficacy, and, possibly, reducing adverse events. In this work, the growing body of evidence is summarized regarding the predictive factors for drug response in patients with AIDs, applying the precision medicine principles to provide high-quality evidence for therapeutic opportunities in improving the management of these patients. © 2020
Συγγραφείς:
Giacomelli, R.
Afeltra, A.
Bartoloni, E.
Berardicurti, O.
Bombardieri, M.
Bortoluzzi, A.
Carubbi, F.
Caso, F.
Cervera, R.
Ciccia, F.
Cipriani, P.
Coloma-Bazán, E.
Conti, F.
Costa, L.
D'Angelo, S.
Distler, O.
Feist, E.
Foulquier, N.
Gabini, M.
Gerber, V.
Gerli, R.
Grembiale, R.D.
Guggino, G.
Hoxha, A.
Iagnocco, A.
Jordan, S.
Kahaleh, B.
Lauper, K.
Liakouli, V.
Lubrano, E.
Margiotta, D.
Naty, S.
Navarini, L.
Perosa, F.
Perricone, C.
Perricone, R.
Prete, M.
Pers, J.-O.
Pitzalis, C.
Priori, R.
Rivellese, F.
Ruffatti, A.
Ruscitti, P.
Scarpa, R.
Shoenfeld, Y.
Triolo, G.
Tzioufas, A.
Λέξεις-κλειδιά:
anakinra; C reactive protein; caspase recruitment domain protein 15; complement component C1q; cryopyrin; disease modifying antirheumatic drug; HLA B27 antigen; hydroxychloroquine; interleukin 12; interleukin 17; interleukin 23; interleukin 6; lymphocyte antigen; phospholipid antibody; protein tnfrsf1a; pyrin; rituximab; steroid; tacrolimus; tocilizumab; tumor necrosis factor; unclassified drug, antiphospholipid syndrome; autoimmune disease; autologous hematopoietic stem cell transplantation; B lymphocyte; comorbidity; diabetes mellitus; drug efficacy; drug response; enthesitis; flow cytometry; helper cell; high risk patient; high risk pregnancy; histopathology; human; humoral immune deficiency; immunotherapy; lupus erythematosus nephritis; non insulin dependent diabetes mellitus; obesity; patient-reported outcome; personalized medicine; plasma exchange; pregnant woman; Review; rheumatoid arthritis; risk factor; Sjoegren syndrome; spondylarthritis; synovitis; systemic lupus erythematosus; systemic sclerosis; treatment outcome; treatment response; autoimmune disease; consensus; personalized medicine; Sjoegren syndrome; systemic lupus erythematosus, Autoimmune Diseases; Consensus; Humans; Lupus Erythematosus, Systemic; Precision Medicine; Sjogren's Syndrome
